A retrospective study of outcomes among SOTR and describe the drug-drug interaction of nirmatrelvir/ritonavir for treatment of COVID-19
Latest Information Update: 01 Aug 2022
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 08 Jun 2022 Results presented at the 2022 American Transplant Congress
- 16 Mar 2022 New trial record
- 12 Mar 2022 Results assessing outcomes among a heterogeneous population of SOTR and quantify the drug-drug interaction with commonly used immunosuppressive medications, published in the American Journal of Transplantation.